Transapical Aortic Valve Procedure Appears Promising
Implantation linked to high technical success, 30-day mortality of 5.1 percent
THURSDAY, Aug. 26 (HealthDay News) -- Transapical aortic valve implantation is associated with favorable outcomes and may be a reasonable choice for treating high-risk patients with severe valve stenosis, according to research published in the Aug. 31 issue of the Journal of the American College of Cardiology.
Miralem Pasic, M.D., of the Deutsches Herzzentrum Berlin, and colleagues analyzed data from 175 patients (mean age, 79.8 years) who underwent transapical aortic valve implantation performed through a mini left anterior thoracotomy. Patients had a mean Society of Thoracic Surgeons score of 23.5.
The researchers found that the technical procedural success was 100 percent, with no cases converting to open heart surgery. Thirty-day mortality was 5.1 percent for the overall group; 8 percent in the first 50 patients; 4 percent in the second 50 patients and last 75 patients; 30 percent for those with cardiogenic shock; and 3.6 percent for those without cardiogenic shock. Twelve-month survival was 82.6 percent.
"Transapical aortic valve implantation already has proved its qualities during the learning curve in our institution. The operative procedure and the equipment are still being evolved and improved. With increased experience and simplified equipment in the future, it is likely that the procedure will become a real alternative to the standard surgical treatment for all patients with aortic valve stenosis, and not only for high-risk patients," the authors conclude.
Several authors disclosed financial relationships with Edwards Lifesciences, maker of the valve used in the study.